The Phase 3 AFFIRM-AL clinical trial was a global, double-blind, placebo-controlled, time-to-event clinical trial that enrolled 207 newly diagnosed, treatment naïve patients with Mayo Stage IV AL ...

Professor of neurology at UCLA and a co-principal investigator, Dr. Steven Cramer, MD affirms, “Reaching Phase 3 in a clinical trial of this scale is a hard-won milestone that has been twelve ...

4D Molecular Therapeutics has initiated its first Phase 3 trial for 4D-150 in wet AMD and expanded its clinical pipeline. Quiver AI Summary. 4D Molecular Therapeutics (4DMT) has announced ...

Candel’s pivotal phase 3 clinical trial in prostate cancer was conducted under a SPA agreed with the FDA. The FDA has also granted Orphan Drug Designation to CAN-2409 for the treatment of PDAC.

Phase 3 HIV Treatment Switch Studies: Key Findings From Recent Clinical Trials. Author(s): Sharon Walmsley, CM, MD, FRCPC .

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans Provided by GlobeNewswire Jul 9, 2025, 12:35:00 PM.

Adial’s Phase 3 trial for AD04 will target genotype-specific subgroups of heavy drinkers with Alcohol Use Disorder. The trial is expected to launch in late 2025, with interim analyses ...

In the current ongoing phase 3 trial, ... Butler J, Miller V, Harrison SA. Integrating liver endpoints in clinical trials of cardiovascular and kidney disease. Nat Med 2024;30:2423-2431. Crossref ...

Brensocatib is an oral, selective, competitive, and reversible inhibitor of DPP-1. 19 In the phase 2 WILLOW trial involving adults with bronchiectasis, treatment with a 10-mg or 25-mg dose of ...

A second phase 3 pivotal clinical trial investigating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia met its primary and key secondary endpoints, according to a press ...

The first patient has been successfully dosed with IBI354 in the phase 3 clinical trial HeriCare-Ovarian01 for patients with platinum-resistant ovarian cancer and HER2 expression, according to the ...